News headlines about Quanterix (NASDAQ:QTRX) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Quanterix earned a news sentiment score of 0.02 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.3304176416934 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Quanterix (QTRX) opened at $19.55 on Wednesday. The firm has a market cap of $424.12 and a price-to-earnings ratio of -12.61. Quanterix has a 52 week low of $15.56 and a 52 week high of $23.70.
Several brokerages have recently issued reports on QTRX. Leerink Swann began coverage on shares of Quanterix in a report on Tuesday. They issued an “outperform” rating and a $27.00 target price for the company. BTIG Research assumed coverage on shares of Quanterix in a research note on Tuesday. They set a “buy” rating and a $26.00 price target for the company. Cowen assumed coverage on shares of Quanterix in a research note on Tuesday. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Quanterix in a research note on Tuesday. They set an “overweight” rating for the company.
Quanterix Company Profile
Quanterix Corporation is a United States-based company, which is a developer of tools in high definition diagnostics. The Company offers single molecule array (Simoa) platform, whcich uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.